Pfizer Inc. (NYSE:PFE)

The common-size income statement reveals a period of significant volatility in profitability and cost structures between 2021 and 2026. While the company maintained strong margins in the early part of the analyzed period, it experienced a severe operational contraction in late 2023, followed by a phased recovery and continued instability in net income due to non-operating items.

Revenue Composition

Revenue streams are primarily driven by product sales, which consistently represent the largest portion of total revenue, fluctuating between 81.07% and 87.75% from 2023 through 2026. Alliance revenues serve as a secondary contributor, typically ranging between 10.73% and 16.19%, while royalty revenues maintain a smaller, relatively stable presence between 1.10% and 2.91% of total revenues.

Gross Profitability and Cost of Sales

Gross profit margins remained robust for the majority of the period, often exceeding 60%. However, a significant anomaly occurred on October 1, 2023, where the cost of sales spiked to 68.70% of revenue, causing gross profit to plummet to 31.30%. This was a sharp departure from the surrounding quarters, such as March 31, 2024, where gross profit peaked at 79.26%. This suggests a temporary but severe impact on production costs or inventory write-downs during the fourth quarter of 2023.

Operating Expense Trends

Selling, informational, and administrative expenses exhibited notable volatility, increasing from a low of 10.10% in April 2022 to a peak of 31.40% by December 31, 2023. Research and development (R&D) spending also saw an upward trend, moving from approximately 9% to 20% of revenue during 2023, indicating a strategic intensification of pipeline investment. Additionally, the amortization of intangible assets showed a steady increase over time, rising from roughly 3% in 2022 to consistently fluctuate between 7% and 9% in the 2024-2026 period.

Operating and Net Income Volatility

Operating income margins were strong in 2021 and 2022, often exceeding 30%. However, the company entered a period of operational loss in late 2023, with operating income dropping to -23.50% and -29.44% in October and December 2023, respectively. While operating margins recovered to between 13% and 28% through 2024 and 2025, the bottom line remained erratic. A substantial deficit in "Other income (deductions)" of -25.72% in December 2025 led to a net loss attributable to common shareholders of -9.38% for that quarter, despite a positive operating margin of 16.36%.

Taxation and Final Net Margins

The provision for taxes has fluctuated significantly, moving between tax benefits and provisions. The net income attributable to common shareholders mirrors the overall volatility of the operating results, swinging from highs of 38.02% in October 2022 to lows of -23.13% in December 2023, eventually stabilizing near 18.59% by March 29, 2026.